作者 | 草履虫编辑 | 晓琳随着礼来、诺和诺德与默沙东相继发布2025年完整财报,2025全球畅销药TOP50新鲜出炉(表1)。数据来源:各大企业财报整理礼来的替尔泊肽(Mounjaro/Zepbound)以365亿美元全年销售额,超越诺和诺德的司美格鲁肽系列(约361亿美元),正式加冕2025年全球药王。而曾蝉联两年药王宝座的默沙东K药(Keytruda),尽管首次突破300亿美元大关至317...
Source Link作者 | 草履虫编辑 | 晓琳随着礼来、诺和诺德与默沙东相继发布2025年完整财报,2025全球畅销药TOP50新鲜出炉(表1)。数据来源:各大企业财报整理礼来的替尔泊肽(Mounjaro/Zepbound)以365亿美元全年销售额,超越诺和诺德的司美格鲁肽系列(约361亿美元),正式加冕2025年全球药王。而曾蝉联两年药王宝座的默沙东K药(Keytruda),尽管首次突破300亿美元大关至317...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.